Racial and ethnic disparities in treatment response and tolerability in multiple sclerosis: A comparative study

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study

(2021) Ludwig Kappos et al.   JAMA Neurology

Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk

(2020) Ruth Dobson et al.   ANNALS OF NEUROLOGY

Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis

(2020) Lisa Thiele née Schrewe et al.   Journal of Neuroinflammation

Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment

(2020) Gauruv Bose et al.   Multiple Sclerosis Journal

A roadmap to precision medicine for multiple sclerosis

(2020) Tanuja Chitnis et al.   Multiple Sclerosis Journal

Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States

(2020) David M. Kern et al.   BMC Neurology

Pharmacogenomic biomarkers in allergy and immunology practice

(2020) David A. Khan et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The Impact of Race on Short Term Treatment Response to Bevacizumab in Diabetic Macular Edema

(2020) Pawarissara Osathanugrah et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Assessment of Racial/Ethnic Disparities in Volumetric MRI Correlates of Clinical Disability in Multiple Sclerosis: A Preliminary Study

(2020) Carlos A. Pérez et al.   JOURNAL OF NEUROIMAGING

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

(2019) J. William L. Brown et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain

(2019) Ramón Morillo Verdugo et al.   Patient Preference and Adherence

Validation of an algorithm for identifying MS cases in administrative health claims datasets

(2019) William J. Culpepper et al.   NEUROLOGY

Race/ethnicity is an independent risk factor for autoimmune hepatitis among the San Francisco underserved

(2018) Briton Lee et al.   AUTOIMMUNITY

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci

(2017) Olga Kulakova et al.   PHARMACOGENOMICS

The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology

(2017) Josephine A. Touma et al.   Translational Cancer Research

Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis

(2016) Lana Zhovtis Ryerson et al.   Therapeutic Advances in Neurological Disorders

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort

(2012) Valéria Coelho Santa Rita Pereira et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

Efficacy of Natalizumab Therapy in Patients of African Descent With Relapsing Multiple Sclerosis

(2011) Bruce A. C. Cree et al.   ARCHIVES OF NEUROLOGY

Multiple sclerosis in Hispanics: a study of clinical disease expression

(2011) L Amezcua et al.   Multiple Sclerosis Journal